-
公开(公告)号:EP1033989A1
公开(公告)日:2000-09-13
申请号:EP98956356.4
申请日:1998-10-30
IPC分类号: A61K31/56
CPC分类号: A61K31/00 , A61K31/56 , A61K31/566 , A61K31/568 , A61K31/569 , A61K31/57 , A61K31/573 , A61K31/575
摘要: The present invention is directed to a method for reducing mast cell mediated allergic reactions, including mast cell mediated allergy and asthma. Mast cell mediated allergic reactions, including type I hypersensitivity response to allergens and asthma, are reduced by administering a dehydroepiandrosterone (DHEA) derivative to a patient in a manner which quickly raises blood levels of the active agent.
-
公开(公告)号:EP3821220B1
公开(公告)日:2024-11-13
申请号:EP19852765.7
申请日:2019-08-21
发明人: LENZI, Tommaso , GABERT, Lukas
-
公开(公告)号:EP4426302A1
公开(公告)日:2024-09-11
申请号:EP22888309.6
申请日:2022-10-31
-
公开(公告)号:EP4408470A1
公开(公告)日:2024-08-07
申请号:EP22877638.1
申请日:2022-09-30
发明人: MAO, Qinwen
IPC分类号: A61K39/395 , C07K16/18 , G01N33/68
CPC分类号: G01N33/6896 , G01N2800/5220130101 , C07K16/18
-
5.
公开(公告)号:EP4328319A3
公开(公告)日:2024-08-07
申请号:EP23200884.7
申请日:2017-10-27
发明人: Oliver, Trudy , Sos, Martin , Wechsler-Reya, Rob
IPC分类号: A01K67/027 , C12N15/09 , C12Q1/02 , A01K67/0278 , A61P35/00 , A61P43/00 , C12Q1/6886 , G01N33/574
CPC分类号: G01N33/57423 , G01N2800/5220130101 , C12Q1/6886 , C12Q2600/10620130101 , C12Q2600/11220130101 , C12Q2600/15820130101 , A01K67/0278 , A01K2217/07220130101 , A01K2217/07520130101 , A01K2217/20620130101 , A01K2227/10520130101 , A01K2267/033120130101 , C12N2999/00720130101 , A61P35/00 , A61P43/00
摘要: Described herein are methods and compositions useful in detecting, diagnosing and treating small cell lung cancer. Transgenic animal models and cell lines are disclosed for the study of a small cell lung cancer subtype. Methods of screening and identifying active agents for the treatment of a small cell lung cancer subtype as well as methods of identifying patients susceptible to treatment with aurora kinase inhibitors are also provided.
-
公开(公告)号:EP4324454A3
公开(公告)日:2024-05-01
申请号:EP23192363.2
申请日:2016-12-06
CPC分类号: A61K9/0048 , A61K33/34 , A61P27/02
摘要: An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.
-
公开(公告)号:EP4355769A1
公开(公告)日:2024-04-24
申请号:EP22825737.4
申请日:2022-06-15
CPC分类号: G01N2333/7820130101 , G01N33/6887 , G01N2800/1020130101 , B01D15/3804 , C07K14/78
-
公开(公告)号:EP2896423B1
公开(公告)日:2024-03-13
申请号:EP15151981.6
申请日:2015-01-21
-
公开(公告)号:EP3576601B1
公开(公告)日:2023-04-19
申请号:EP18747512.4
申请日:2018-01-31
-
公开(公告)号:EP3628665B1
公开(公告)日:2022-11-02
申请号:EP19189727.1
申请日:2012-03-31
发明人: Bearss, David J. , Vankayalapati, Hariprasad , Mollard, Alexis , Warner, Steven L. , Sharma, Sunil
IPC分类号: C07D239/42 , A61K31/506 , A61P35/00
-
-
-
-
-
-
-
-
-